486 related articles for article (PubMed ID: 12507560)
1. The von Hippel-Lindau tumor suppressor, hypoxia-inducible factor-1 (HIF-1) degradation, and cancer pathogenesis.
Pugh CW; Ratcliffe PJ
Semin Cancer Biol; 2003 Feb; 13(1):83-9. PubMed ID: 12507560
[TBL] [Abstract][Full Text] [Related]
2. Regulation of HIF by the von Hippel-Lindau tumour suppressor: implications for cellular oxygen sensing.
Mole DR; Maxwell PH; Pugh CW; Ratcliffe PJ
IUBMB Life; 2001 Jul; 52(1-2):43-7. PubMed ID: 11795592
[TBL] [Abstract][Full Text] [Related]
3. The tumour suppressor protein VHL targets hypoxia-inducible factors for oxygen-dependent proteolysis.
Maxwell PH; Wiesener MS; Chang GW; Clifford SC; Vaux EC; Cockman ME; Wykoff CC; Pugh CW; Maher ER; Ratcliffe PJ
Nature; 1999 May; 399(6733):271-5. PubMed ID: 10353251
[TBL] [Abstract][Full Text] [Related]
4. Von Hippel-Lindau tumor suppressor protein and hypoxia-inducible factor in kidney cancer.
Maynard MA; Ohh M
Am J Nephrol; 2004; 24(1):1-13. PubMed ID: 14654728
[TBL] [Abstract][Full Text] [Related]
5. Hypoxia inducible factor-alpha binding and ubiquitylation by the von Hippel-Lindau tumor suppressor protein.
Cockman ME; Masson N; Mole DR; Jaakkola P; Chang GW; Clifford SC; Maher ER; Pugh CW; Ratcliffe PJ; Maxwell PH
J Biol Chem; 2000 Aug; 275(33):25733-41. PubMed ID: 10823831
[TBL] [Abstract][Full Text] [Related]
6. Contrasting effects on HIF-1alpha regulation by disease-causing pVHL mutations correlate with patterns of tumourigenesis in von Hippel-Lindau disease.
Clifford SC; Cockman ME; Smallwood AC; Mole DR; Woodward ER; Maxwell PH; Ratcliffe PJ; Maher ER
Hum Mol Genet; 2001 May; 10(10):1029-38. PubMed ID: 11331613
[TBL] [Abstract][Full Text] [Related]
7. Up-regulation of hypoxia-inducible factors HIF-1alpha and HIF-2alpha under normoxic conditions in renal carcinoma cells by von Hippel-Lindau tumor suppressor gene loss of function.
Krieg M; Haas R; Brauch H; Acker T; Flamme I; Plate KH
Oncogene; 2000 Nov; 19(48):5435-43. PubMed ID: 11114720
[TBL] [Abstract][Full Text] [Related]
8. von Hippel-Lindau protein mutants linked to type 2C VHL disease preserve the ability to downregulate HIF.
Hoffman MA; Ohh M; Yang H; Klco JM; Ivan M; Kaelin WG
Hum Mol Genet; 2001 May; 10(10):1019-27. PubMed ID: 11331612
[TBL] [Abstract][Full Text] [Related]
9. The von Hippel-Lindau tumor suppressor protein: new insights into oxygen sensing and cancer.
Kim W; Kaelin WG
Curr Opin Genet Dev; 2003 Feb; 13(1):55-60. PubMed ID: 12573436
[TBL] [Abstract][Full Text] [Related]
10. The von Hippel-Lindau tumor suppressor gene.
Kondo K; Kaelin WG
Exp Cell Res; 2001 Mar; 264(1):117-25. PubMed ID: 11237528
[TBL] [Abstract][Full Text] [Related]
11. Identification of residues critical for regulation of protein stability and the transactivation function of the hypoxia-inducible factor-1alpha by the von Hippel-Lindau tumor suppressor gene product.
Pereira T; Zheng X; Ruas JL; Tanimoto K; Poellinger L
J Biol Chem; 2003 Feb; 278(9):6816-23. PubMed ID: 12468553
[TBL] [Abstract][Full Text] [Related]
12. Targeting of HIF-alpha to the von Hippel-Lindau ubiquitylation complex by O2-regulated prolyl hydroxylation.
Jaakkola P; Mole DR; Tian YM; Wilson MI; Gielbert J; Gaskell SJ; von Kriegsheim A; Hebestreit HF; Mukherji M; Schofield CJ; Maxwell PH; Pugh CW; Ratcliffe PJ
Science; 2001 Apr; 292(5516):468-72. PubMed ID: 11292861
[TBL] [Abstract][Full Text] [Related]
13. Identification of cyclin D1 and other novel targets for the von Hippel-Lindau tumor suppressor gene by expression array analysis and investigation of cyclin D1 genotype as a modifier in von Hippel-Lindau disease.
Zatyka M; da Silva NF; Clifford SC; Morris MR; Wiesener MS; Eckardt KU; Houlston RS; Richards FM; Latif F; Maher ER
Cancer Res; 2002 Jul; 62(13):3803-11. PubMed ID: 12097293
[TBL] [Abstract][Full Text] [Related]
14. Identification of novel VHL target genes and relationship to hypoxic response pathways.
Maina EN; Morris MR; Zatyka M; Raval RR; Banks RE; Richards FM; Johnson CM; Maher ER
Oncogene; 2005 Jun; 24(28):4549-58. PubMed ID: 15824735
[TBL] [Abstract][Full Text] [Related]
15. Mechanism of regulation of the hypoxia-inducible factor-1 alpha by the von Hippel-Lindau tumor suppressor protein.
Tanimoto K; Makino Y; Pereira T; Poellinger L
EMBO J; 2000 Aug; 19(16):4298-309. PubMed ID: 10944113
[TBL] [Abstract][Full Text] [Related]
16. The von Hippel-Lindau tumor suppressor protein.
Ivan M; Kaelin WG
Curr Opin Genet Dev; 2001 Feb; 11(1):27-34. PubMed ID: 11163147
[TBL] [Abstract][Full Text] [Related]
17. The pVHL-hIF-1 system. A key mediator of oxygen homeostasis.
Maxwell PH; Pugh CW; Ratcliffe PJ
Adv Exp Med Biol; 2001; 502():365-76. PubMed ID: 11950150
[TBL] [Abstract][Full Text] [Related]
18. Hypoxia-inducible factor-1 (HIF-1) promotes its degradation by induction of HIF-alpha-prolyl-4-hydroxylases.
Marxsen JH; Stengel P; Doege K; Heikkinen P; Jokilehto T; Wagner T; Jelkmann W; Jaakkola P; Metzen E
Biochem J; 2004 Aug; 381(Pt 3):761-7. PubMed ID: 15104534
[TBL] [Abstract][Full Text] [Related]
19. Molecular targets from VHL studies into the oxygen-sensing pathway.
Maynard MA; Ohh M
Curr Cancer Drug Targets; 2005 Aug; 5(5):345-56. PubMed ID: 16101382
[TBL] [Abstract][Full Text] [Related]
20. Carboxyl-terminal transactivation activity of hypoxia-inducible factor 1 alpha is governed by a von Hippel-Lindau protein-independent, hydroxylation-regulated association with p300/CBP.
Sang N; Fang J; Srinivas V; Leshchinsky I; Caro J
Mol Cell Biol; 2002 May; 22(9):2984-92. PubMed ID: 11940656
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
